Spiramycin
| Code | Size | Price |
|---|
| TAR-T0819-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T0819-100mg | 100mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Spiramycin is a macrolide antibiotic produced by Streptomyces ambofaciens. The drug is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci. It is used to treat infections caused by bacteria and Toxoplasma gondii.
CAS:
8025-81-8
Formula:
C43H74N2O14
Molecular Weight:
843.065
Pathway:
Microbiology/Virology
Purity:
0.9792
SMILES:
CO[C@H]1[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C
Target:
Antibacterial; Antibiotic; Parasite
References
1. Poulsen SM, et al. J Mol Biol, 2000, 304(3), 471-481.
2. Brisson-No?l A, et al. J Antimicrob Chemother, 1988, 22, 13-23.
3. Menninger JR, et al. Antimicrob Agents Chemother, 1982, 21(5), 811-818.
4. Roche Y, et al. J Antimicrob Chemother, 1986, 17(2), 195-203.
5. Bailly S, et al. Antimicrob Agents Chemother, 1991, 35(10), 2016-2019.
6. Etewa SE, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018 Mar;42(1):102-113.